Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutated non-small cell lung cancer

被引：0
|
作者：
Aredo, Jacqueline V.
Urisman, Anatoly
Gubens, Matthew A.
Mulvey, Claire
Allen, Greg M.
Rotow, Julia K.
Kerr, Daniel Lucas
Chakrabarti, Turja
Bacaltos, Bianca
Gee, Megan
Jones, Kirk
Aisner, Dara L.
Patil, Tejas
Schenk, Erin Lynn
Bivona, Trever G.
Riess, Jonathan W.
Coleman, Melissa
Kratz, Johannes Ruediger
Jablons, David
Blakely, Collin M.
机构：
[1] Univ Calif San Francisco, San Francisco, CA USA
[2] Dana Farber Canc Inst, Boston, MA USA
[3] Univ Colorado, Aurora, CO USA
[4] Univ Colorado, Comprehens Canc Ctr, Aurora, CO USA
[5] Univ Colorado, Anschutz Med Campus, Aurora, CO USA
[6] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8508
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer: Updated Results
    Blakely, C.
    Urisman, A.
    Kerr, D.
    Wu, W.
    Bacaltos, B.
    Rotow, J.
    Gubens, M.
    Jones, K.
    Bivona, T.
    Joo, S.
    Riess, J.
    Aisner, D.
    Doebele, R.
    Patil, T.
    Schenk, E.
    Kratz, J.
    Jablons, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1039 - S1040
  • [2] A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer
    Rotow, J.
    Urisman, A.
    Mccoach, C.
    Jahan, T.
    Bivona, T.
    Jones, K.
    Gupta, A.
    Do, H.
    Riess, J.
    Aisner, D.
    Doebele, R.
    Jablons, D.
    Kratz, J.
    Blakely, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S578 - S578
  • [3] Safety of osimertinib in EGFR-mutated non-small cell lung cancer
    Mezquita, Laura
    Varga, Andreea
    Planchard, David
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1239 - 1248
  • [4] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Alessandro Leonetti
    Sugandhi Sharma
    Roberta Minari
    Paola Perego
    Elisa Giovannetti
    Marcello Tiseo
    British Journal of Cancer, 2019, 121 : 725 - 737
  • [5] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Leonetti, Alessandro
    Sharma, Sugandhi
    Minari, Roberta
    Perego, Paola
    Giovannetti, Elisa
    Tiseo, Marcello
    BRITISH JOURNAL OF CANCER, 2019, 121 (09) : 725 - 737
  • [6] Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
    Aredo, Jacqueline, V
    Wakelee, Heather A.
    Neal, Joel W.
    Padda, Sukhmani K.
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2022, 30
  • [7] Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA
    Tsuboi, Masahiro
    Weder, Walter
    Escriu, Carles
    Blakely, Collin
    He, Jianxing
    Dacic, Sanja
    Yatabe, Yasushi
    Zeng, Lingmin
    Walding, Andrew
    Chaft, Jamie E.
    FUTURE ONCOLOGY, 2021, 17 (31) : 4045 - 4055
  • [8] MERTK Activation Drives Osimertinib Resistance in EGFR-Mutated Non-Small Cell Lung Cancer
    Yan, D.
    Huelse, J.
    Parker, R.
    Wang, X.
    Frye, S.
    Earp, H. S.
    Deryckere, D.
    Graham, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1147 - S1147
  • [9] Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?
    Leonetti, Alessandro
    Facchinetti, Francesco
    Tiseo, Marcello
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6
  • [10] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
    Fu, Kai
    Xie, Fachao
    Wang, Fang
    Fu, Liwu
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
12345